Drug Profile
PL 101
Alternative Names: PL101Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Polyrizon
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis; Ragweed pollen hypersensitivity
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in Israel (Intranasal, Spray)
- 28 Aug 2019 No recent reports of development identified for clinical-Phase-Unknown development in Ragweed pollen hypersensitivity in Israel (Intranasal, Spray)